Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein

Tada, S
Departments of Internal Medicine 11, Pathology 11, and Neuropathology, Faculty of Medicine

Iida, M
Departments of Internal Medicine 11, Pathology 11, and Neuropathology, Faculty of Medicine

Yao, T
Department of Gastroenterology, Fukuoka University, Chikushi Hospital | Departments of Internal Medicine 11, Pathology 11, and Neuropathology, Faculty of Medicine

Kitamoto, T
Departments of Internal Medicine 11, Pathology 11, and Neuropathology, Faculty of Medicine

他

http://hdl.handle.net/2324/5569
Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein

S Tada, M Iida, T Yao, T Kitamoto, T Yao, M Fujishima

Abstract
A clinicopathologic study was made of 16 patients with amyloidosis and with clinical signs of intestinal pseudo-obstruction. Amyloid deposits in the small intestine were proved in all cases by endoscopic or intraoperative biopsies, and immunohistochemical study identified the chemical types of amyloid protein: amyloid A protein (AA) in 13 cases, light chain protein (AL) in two, and β₂-microglobulin (AH) in one. Clinically, an acute self-limiting obstructive condition was evident in 13 cases with AA, and 12 of them returned to normal bowel function after receiving total parenteral nutrition. Two cases with AL and one with AH presented chronic, intermittent, obstructive symptoms, and medical treatment, including total parenteral nutrition, was ineffective with no recovery of intestinal propulsion. Pathological examination of the necropsy specimens in seven cases showed considerable differences in the preferential sites of gastrointestinal deposits between the chemical types of amyloid; extensive infiltration and replacement of the muscularis propria by amyloid deposits throughout the gastrointestinal tract, especially the small intestine, were found in the AL and the AH cases, while amyloid deposits in the myenteric plexus without appreciable muscle infiltration were shown in the AA cases. These results show that intestinal pseudo-obstruction in patients with amyloidosis is caused by either myopathy or neuropathy, and that chemical types of amyloid may determine which of the two factors has the dominant affect on the bowel function.

Methods

PATIENTS
Between 1978 and 1992, we saw 17 patients with amyloidosis who presented with clinical signs of intestinal obstruction. Of these, 11 patients initially came to the hospital complaining of abdominal distension, cramping, anorexia, vomiting, constipation or diarrhoea, and we found six in whom such clinical signs developed during the follow up of illness. The abdominal plain films of these patients showed abnormal accumulation of gastrointestinal gas, dilated loops of the small and large bowel, with occasional air-fluid values. Two patients had emergency laparotomy and no mechanical obstruction was found. In the other 14 patients, barium studies of the small and large intestine did not show any mechanical obstruction. The remaining patient showed a large mass in the jejunum, which was histopathologically diagnosed as an amyloid tumor. Excluding this exceptional case, we examined 16 patients showing clinical signs of intestinal pseudo-obstruction.

IDENTIFICATION OF AMYLOID PROTEIN
One patient had primary amyloidosis, two had myeloma associated amyloidosis, one had haemodialysis associated amyloidosis, and 12 had secondary amyloidosis (rheumatoid arthritis in eight, ankylosing spondylitis in one, adult Still's disease in one, polymyositis in one, and immunoglobulin origin, is found in primary or myeloma-associated amyloidosis. Secondary amyloidosis associated with chronic inflammatory diseases consists of amyloid A (AA) protein, AH amyloid consisting of β₂-microglobulin is found in patients receiving longterm haemodialysis. It is now widely recognised that amyloidosis, rather than being a single disease entity, represents a group of diseases that have in common characteristic microscopic staining properties and electron microscopic fibrillar configuration. Correlations between the chemical types, however, of amyloid and histological or clinical features in amyloidosis patients with intestinal pseudo-obstruction have never been determined.

The aims of this study were: (a) to explore the distinguishing clinical characteristics between the patients with three types of amyloidosis who presented with clinical signs of intestinal pseudo-obstruction, and (b) to examine the relations between the clinical features and pathological findings.

Identification of amyloid protein

Several different types of amyloid fibril protein exist in systemic amyloidosis. Light chain protein (AL) amyloid, which is of
Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein

Table 1: Summary of the clinical data from amyloidosis patients with intestinal pseudo-obstruction

<table>
<thead>
<tr>
<th>Case no</th>
<th>Age (y) and sex</th>
<th>Underlying disease</th>
<th>Chemical type of amyloid</th>
<th>Onset of obstructive symptoms (duration)</th>
<th>Treatment</th>
<th>Ileus reversibility</th>
<th>Interval between diagnosis and death or survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>77 M</td>
<td>Multiple myeloma</td>
<td>AL</td>
<td>Chronic (2 y 3 mnth)</td>
<td>TPN, Ch, M</td>
<td>Irreversible</td>
<td>1 mnth died</td>
</tr>
<tr>
<td>2</td>
<td>51 F</td>
<td>Multiple myeloma</td>
<td>AL</td>
<td>Chronic (2 y)</td>
<td>TPN, Ch, M</td>
<td>Irreversible</td>
<td>2 mnth died</td>
</tr>
<tr>
<td>3</td>
<td>42 M</td>
<td>Chronic haemodialysis</td>
<td>AH</td>
<td>Chronic (2 y 10 mnth)</td>
<td>M-A tube, TPN, Ch, M, Ci</td>
<td>Irreversible</td>
<td>2 y 3 mnth died</td>
</tr>
<tr>
<td>4</td>
<td>65 M</td>
<td>Rheumatoid arthritis</td>
<td>AA</td>
<td>Acute (3 wk)</td>
<td>TPN, M, Ci</td>
<td>Irreversible</td>
<td>3 wk died</td>
</tr>
<tr>
<td>5</td>
<td>66 F</td>
<td>Rheumatoid arthritis</td>
<td>AA</td>
<td>Acute (6 wk)</td>
<td>TPN, M, Ci</td>
<td>Irreversible</td>
<td>2 mnth died</td>
</tr>
<tr>
<td>6</td>
<td>42 F</td>
<td>Rheumatoid arthritis</td>
<td>AA</td>
<td>Acute (4 wk)</td>
<td>TPN, M, Ci</td>
<td>Irreversible</td>
<td>3 y 1 mnth died</td>
</tr>
<tr>
<td>7</td>
<td>24 F</td>
<td>Polymyositis</td>
<td>AA</td>
<td>Subacute (10 wk)</td>
<td>TPN, M, Ci</td>
<td>Reversible</td>
<td>5 y 8 mnth died</td>
</tr>
<tr>
<td>8</td>
<td>62 F</td>
<td>Rheumatoid arthritis</td>
<td>AA</td>
<td>Acute (8 wk)</td>
<td>TPN, M, Ci</td>
<td>Reversible</td>
<td>4 y 2 mnth alive</td>
</tr>
<tr>
<td>9</td>
<td>52 M</td>
<td>Ankylosing spondylitis</td>
<td>AA</td>
<td>Acute (4 wk)</td>
<td>TPN, M, Ci</td>
<td>Reversible</td>
<td>8 y 10 mnth alive</td>
</tr>
<tr>
<td>10</td>
<td>47 F</td>
<td>Rheumatoid arthritis</td>
<td>AA</td>
<td>Acute (5 wk)</td>
<td>TPN, M, Ci</td>
<td>Reversible</td>
<td>2 y 5 mnth alive</td>
</tr>
<tr>
<td>11</td>
<td>44 M</td>
<td>Rheumatoid arthritis</td>
<td>AA</td>
<td>Acute (3 wk)</td>
<td>TPN, M, Ci</td>
<td>Reversible</td>
<td>1 y 11 mnth died</td>
</tr>
<tr>
<td>12</td>
<td>42 M</td>
<td>Adult Still's disease</td>
<td>AA</td>
<td>Subacute (34 wk)</td>
<td>M-A tube, TPN</td>
<td>Reversible</td>
<td>6 y 10 mnth alive</td>
</tr>
<tr>
<td>13</td>
<td>36 M</td>
<td>Rheumatoid arthritis</td>
<td>AA</td>
<td>Acute (8 wk)</td>
<td>TPN, M, Ci</td>
<td>Reversible</td>
<td>2 y 4 mnth alive</td>
</tr>
<tr>
<td>14</td>
<td>34 F</td>
<td>Rheumatoid arthritis</td>
<td>AA</td>
<td>Acute (4 wk)</td>
<td>TPN, M, Ci</td>
<td>Reversible</td>
<td>4 y 3 mnth alive</td>
</tr>
<tr>
<td>15</td>
<td>30 F</td>
<td>None</td>
<td>AA</td>
<td>Subacute (10 wk)</td>
<td>TPN, M, Ci</td>
<td>Reversible</td>
<td>10 y 7 mnth alive</td>
</tr>
<tr>
<td>16</td>
<td>23 M</td>
<td>Crohn's disease</td>
<td>AA</td>
<td>Acute (9 wk)</td>
<td>TPN, M, Ci</td>
<td>Reversible</td>
<td>6 y 6 mnth alive</td>
</tr>
</tbody>
</table>

TPN = total parenteral nutrition, Ch = cholinergic agents, M = metoclopramide, M-A = Miller-Abbott tube, Ci = cisapride, P = prednisolone. AA = amyloid A protein, AL = light chain protein, AH = ß2-microglobulin protein.

*We could not evaluate the ileus reversibility because this patient died of renal failure and sepsis shortly after admission to hospital.

Crohn's disease in one). Using a long duodeno-fibrescope, endoscopic biopsy specimens of the jejunum showed amyloid deposits in 15 patients. In the remaining patient, amyloid deposits of the jejunum were confirmed by intraoperative biopsy specimens. Using these specimens, chemical types of amyloid protein were identified by the avidin-biotin complex (ABC) method using anti-AA, anti-ß2-microglobulin (1:500, Dako), and anti-prealbumin (1:500, Dako) antibodies. For a comparative evaluation of amyloid protein, potassium permanganate (KMnO4) treatment was performed before staining with Congo red. AA protein was identified by positive staining with anti-AA antibody and sensitivity to KMnO4 reaction, while AL protein failed to stain with anti-AA, anti-ß2-microglobulin, and anti-prealbumin antibodies, and was resistant to KMnO4 reaction. AA protein was shown by positive staining with anti-ß2-microglobulin antibody and by negative staining with other antibodies.

Necropsy Examination

Of the 16 patients, three died at the time of their first hospital admission and five died subsequently. Postmortem examination was carried out in seven patients, and the gastrointestinal tract was fixed in 10% neutral buffered formalin. From each of the oesophagus (lower third), stomach (fundus and antrum), duodenum (second portion), jejunum (within 50 cm from the Treitz ligament), ileum (within 50 cm from...
TABLE II
Histological findings of the small intestine in seven necropsy cases with intestinal pseudo-obstruction

<table>
<thead>
<tr>
<th>Case no</th>
<th>Chemical types of amyloid</th>
<th>Muscularis propria</th>
<th>Myenteric plexuses</th>
<th>Vessels</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Amyloid deposits</td>
<td>Muscle replacement</td>
<td>Amyloid deposits</td>
</tr>
<tr>
<td>1</td>
<td>AL</td>
<td>++</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>2</td>
<td>AL</td>
<td>++ to +++</td>
<td>++ to +++</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>AH</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>AA</td>
<td>+ to +</td>
<td>++ to +++</td>
<td>+</td>
</tr>
<tr>
<td>5</td>
<td>AA</td>
<td>- to +</td>
<td>++ to +++</td>
<td>-</td>
</tr>
<tr>
<td>6</td>
<td>AA</td>
<td>+</td>
<td>++ to +++</td>
<td>+</td>
</tr>
<tr>
<td>7</td>
<td>AA</td>
<td>+</td>
<td>++ to +++</td>
<td>+</td>
</tr>
</tbody>
</table>

- absent, + mild, ++ moderate, +++ severe. Other abbreviations as in Table I.

Results
CHEMICAL TYPES OF AMYLOID PROTEIN
According to the results of immunohistochemistry and sensitivity to KMnO₄ reaction, there were 13 patients with AA amyloidosis, two with AL, and one with AH. Good correlation was noted between clinical classification and the expected amyloid type in 15 of 16 patients; the 12 patients with secondary amyloidosis had AA, two with multiple myeloma had AL, and one with long-term haemodialysis had AH. An exceptional case, who was clinically classified as primary amyloidosis because no predisposing disease could be recognised, showed deposits of AA protein as evidenced by a positive stain for anti-AA antibody, which was sensitive to KMnO₄ reaction.

CLINICAL FEATURES
All 16 patients suffered from similar symptoms such as nausea, vomiting, abdominal distension, and pain. The patients had either diarrhoea or constipation. Malnutrition was evident in all patients whose laboratory data showed hypoalbuminaemia (mean (SD) was 2.6 (0.6) mg/dl, ranging from 1.0 to 3.5 mg/dl). The duration of obstructive symptoms varied widely with a range from a few weeks to several years. Thirteen had an acute or subacute self-limiting condition, but the remaining three had several years history of recurrent obstructive symptoms. Table I summarises the clinical features and chemical types of amyloid protein.

We found differences in the clinical signs between amyloid types. The patients with AL and AH presented with chronic, intermittent, obstructive symptoms, which developed into a severe form that required admission to hospital. The patients with AA had no chronic obstructive symptoms until they developed an acute condition with apparent intestinal obstruction. In all patients, plain films of the abdomen showed abnormal gastrointestinal gas. Considerable gaseous dilatation of the small and large bowel was consistently seen in the AL and the AH patients during their hospital stay (Fig 1), whereas the abnormal gas disappeared after treatment in 12 of 13 patients with AA (Fig 2).

All patients received total parenteral nutrition treatment. The daily maintenance dose of calories was 2000 to 2400 kcal (40–60 kcal/kg body weight). The average period of treatment was 10–13 (6–28) weeks, ranging from 2 to 28 weeks. One patient with AA died shortly after the start of total parenteral nutrition because of renal failure and sepsis. In 12 patients, all of whom were AA, total parenteral nutrition was effective in improving symptoms and signs, and thereafter, made it possible to maintain adequate oral intake again. In these AA patients, there was

Figure 3:
Light chain protein (AL) amyloidosis (case 1). Section of jejunum showing extensive amyloid deposits in the muscularis propria and muscle tissue replaced by amyloid (top, haematoxylin and eosin (original magnification ×45); bottom, Congo red stain with polarised light (original magnification ×50)).
no recurrence of paralytic ileus or severe obstructive symptoms during the follow up ranging from 1.9 to 10.6 years (average 5.1 years), although minor symptoms occasionally occurred. In the remaining three patients (AL in two and AH in one), however, the obstructive symptoms were persistent and quite resistant to total parenteral nutrition treatment. Medical treatments such as cholinergic agents, metoclopramide, and cisapride were also ineffective. All of them eventually died of cardiac failure without the return to normal bowel function.

**Discussion**

The main finding of this study is that if intestinal pseudo-obstruction develops in patients with amyloidosis, the clinical features are considerably different according to the chemical types of amyloid protein. Acute or subacute self-limiting

**Figure 4:** AH amyloidosis (case 3). Jejunal specimens showing massive amyloid deposits in the muscularis propria and slight deposits in the submucosal vessels (arrow) (left). Congo red stain, right; avidin-biotin complex method with anti-β2-microglobulin antibody (brown reaction product); original magnification ×80.

**Figure 5:** AA amyloidosis (case 4). Section of jejunum showing massive amyloid deposits in Auerbach’s plexus. The nerve bundles and ganglion cells are compressed by amyloid and show atrophic changes (haematoxylin and eosin stain original magnification ×350).

**Necropsy Findings**

In all seven necropsy cases, amyloid was found in every site of the gastrointestinal tract including the oesophagus, stomach, small, and large intestines. Table II shows the degree of amyloid deposition and destruction of organic structures in the muscularis propria, myenteric plexuses, and blood vessels of the small intestine. In comparing the AA, AL, and AH cases, we found an appreciable difference in the degree of amyloid deposits in the muscularis propria. By contrast with negative or slight smooth muscle infiltration in the AA cases, the muscularis was quite extensively affected in the AL (Fig 3) and the AH cases (Fig 4). In cases with massive deposits, there were degenerative changes in muscle fibres, with muscle tissue being replaced by amyloid.

Amyloid was found in the myenteric plexuses in the AA cases (Fig 5). The degree of amyloid deposition in the myenteric plexuses varied widely; some were free of amyloid in certain areas, while massive amyloid deposits were evident in others. In plexuses with amyloid deposits, some residual ganglion cells showed degenerative changes. In the AL and AH cases, we could not find any amyloid in the myenteric plexuses. Many Auerbach’s plexuses were compressed, however, by the surrounding abundant amyloid deposits, with a diminution in their number and the presence of degenerative ganglion cells.

In all cases, vascular deposits of amyloid were found most commonly in the submucosa. Massive vascular deposits were found in the AA cases, while the degree was moderate in the AL and slight in the AH.

These histological findings were similar in all parts of the gastrointestinal tract. The degree of amyloid deposition, however, was greatest in the small intestine.

**Discussion**

The main finding of this study is that if intestinal pseudo-obstruction develops in patients with amyloidosis, the clinical features are considerably different according to the chemical types of amyloid protein. Acute or subacute self-limiting
intestinal pseudo-obstruction (so called paralytic ileus) occurred in patients with AA amyloidosis and bowel function was usually restored by conservative treatment. Conversely, chronic intestinal pseudo-obstruction, which is manifested clinically by recurrent attacks of obstructive conditions, occurred in the patients with AL and AH amyloidosis, with failure of intestinal propulsion to return.

Abnormalities of gastrointestinal motility may occur in all forms of amyloidosis and intestinal pseudo-obstruction has been reported in secondary or primary amyloidosis, including amyloidosis associated with multiple myeloma. Although the mechanisms of impaired motility have not been fully defined, infiltration of intestinal smooth muscle and gastrointestinal neuropathy with amyloid involvement of the autonomic nerves have been reported. It has not been concluded, however, which of the two factors dominantly affects the bowel motor function, and the relation between motility disorders and chemical types of amyloid has not been examined.

In this study, the most striking histological finding was the presence of extensive amyloid infiltration of the smooth muscle in the AL and the AH cases, but such amyloid deposits were not seen in the AA cases. If the amyloid almost totally replaces smooth muscle, intestinal propulsion to return. Once massive amyloid deposits occur in the muscularis propria, this myopathy is thought to be an irreversible change because of the difficulty of elimination of this insoluble protein. This may also explain the finding that the AL and the AH cases in this study did not respond to any treatment and had a poor prognosis when they presented with severe intestinal obstruction. The possibility exists, however, that some treatments may be effective when the smooth muscle amyloid infiltration is not so extensive, as shown in a case of Fraser et al. which was responsive to cisapride.

Gilat et al. studied 68 cases of systemic amyloidosis affecting the gastrointestinal tract, and showed that parenchymal deposition predominated in the muscularis propria in primary or myeloma associated amyloidosis, while in secondary amyloidosis it was mainly distributed in the lamina propria mucosa. In reviewing reports on amyloidosis patients with intestinal pseudo-obstruction, the patients with multiple myeloma tend to have extensive smooth muscle infiltration. These studies support our findings that clinically significant amyloid deposits in the muscularis propria are more likely in AL amyloidosis than in AA.

Recently, a new form of amyloid protein associated with longterm haemodialysis has been identified as $\beta_2$-microglobulin. Gastrointestinal involvement by amyloid has been reported in dialysis patients, and there have been cases of intestinal infarction associated with massive amyloid deposits in the muscle layers of the bowel. Although only a few cases have been studied, it seems probable that extensive infiltration and smooth muscle replacement by amyloid deposits occur in patients with AH amyloidosis, as shown in our case.

Myenteric plexuses often participate in familial amyloid polyneuropathy and in a few cases with AL and AA. In this study, pathological examination of the necropsy specimens showed that amyloid deposits in the myenteric plexuses were seen only in the AA cases. Interestingly, 12 of our 13 patients with AA showed a remarkable improvement in bowel function after receiving total parenteral nutrition treatment. Although total parenteral nutrition does nothing to treat the primary disease directly, it helps the patient receive enough nutrition until bowel functions return to normal again. Our clinical findings suggest that the neuronal disorder may be compensated to some degree because the intestines are richly innervated. If the muscularis propria escapes extensive damage, we assume that the impaired bowel propulsion is allowed to recover to some extent. On the other hand, vascular insufficiency might also have contributed to the impaired peristalsis, because appreciable vascular deposits were seen in our AA cases. Further examinations are required, however, to know the exact correlation between them.

In this study, differences in the histological sites of amyloid deposits between the chemical types of amyloid affect the clinical signs of intestinal pseudo-obstruction. Our findings suggest that this disease usually runs a more serious course in AL and AH than in AA. Recent reports show that clinical and histological differences in the preferential sites of amyloid deposition between the chemical types of amyloid exist in the heart, kidney, spleen. In the heart, clinically significant cardiac amyloid with congestive heart failure is more likely in AL than in AA, because extensive amyloid interstitial infiltration in the myocardium is more often seen in AL than in AA. In patients with amyloidosis, therefore, we believe that chemical typing of the amyloid protein is very important in predicting the clinical characteristics, course, and prognosis of the disease.

We thank Mr Peter Flaherty for his assistance in preparation of the manuscript.

Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein


